mutated Ligand Binding Site gene DataBase





About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for CPB2
Gene summary
Basic gene Info.Gene symbolCPB2
Gene namecarboxypeptidase B2 (plasma)
CytomapUCSC genome browser: 13q14.11
Type of geneprotein-coding
Descriptioncarboxypeptidase B-like proteincarboxypeptidase B2carboxypeptidase B2 (plasma, carboxypeptidase U)carboxypeptidase Rthrombin-activable fibrinolysis inhibitorthrombin-activatable fibrinolysis inhibitor
Modification date20141207
dbXrefs MIM : 603101
Ensembl : ENSG00000080618
HPRD : 04374
Vega : OTTHUMG00000016867
ProteinUniProt: Q96IY4
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_CPB2
BioGPS: 1361
PathwayNCI Pathway Interaction Database: CPB2
Pathway Commons: CPB2
ContextiHOP: CPB2
ligand binding site mutation search in PubMed: CPB2
UCL Cancer Institute: CPB2
Assigned class in mutLBSgeneDBB: This gene belongs to targetable_mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez

Ligand binding site mutations for CPB2

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.

Protein structure related information for CPB2
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for CPB2 from PDB

Differential gene expression and gene-gene network for CPB2
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of CPB2 and the right PPI network was created from samples without mutations in the LBS of CPB2. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Phenotype information for CPB2
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Pharmacological information for CPB2
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure
InvestigationalDB05712AZD-9684Small molecule

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of CPB2 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS

Conservation information for LBS of CPB2
Multiple alignments for Q96IY4 in multiple species
LBSAA sequence# speciesSpecies
A365ESLYLAPGGSD3Bos taurus, Mus musculus, Rattus norvegicus
A365ETLYLAPGGGD1Homo sapiens
D370APGGSDDWIYD3Bos taurus, Mus musculus, Rattus norvegicus
D370APGGGDDWIYD1Homo sapiens
E184GIHAREWISPA4Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus
E385YSFTIELRDTG3Homo sapiens, Mus musculus, Rattus norvegicus
E385YSFTFELRDKG1Bos taurus
H181IDCGIHAREWI4Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus
H310AYISMHSYSQQ2Mus musculus, Rattus norvegicus
H310AYISMHSYSQH1Homo sapiens
H310AYISMHSYSQK1Bos taurus
L362SGSESLYLAPG3Bos taurus, Mus musculus, Rattus norvegicus
L362HGSETLYLAPG1Homo sapiens
N256VGTDLNRNFAS3Bos taurus, Mus musculus, Rattus norvegicus
N256IGTDLNRNFAS1Homo sapiens
R239KNRMWRKNRSF1Homo sapiens
R239KDRMWRKNRSL1Bos taurus
R239KNRMWRKNRSA1Mus musculus
R239KNRMWRKNRSV1Rattus norvegicus
R257GTDLNRNFASK4Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus
S311YISMHSYSQQI2Mus musculus, Rattus norvegicus
S311YISMHSYSQHI1Homo sapiens
S311YISMHSYSQKI1Bos taurus
S321ILFPYSYNRSK2Mus musculus, Rattus norvegicus
S321IVFPYSYTRSK1Homo sapiens
S321IVFPYSYSRSR1Bos taurus
T383IKYSFTIELRD3Homo sapiens, Mus musculus, Rattus norvegicus
T383IKYSFTFELRD1Bos taurus
Y312ISMHSYSQQIL2Mus musculus, Rattus norvegicus
Y312ISMHSYSQHIV1Homo sapiens
Y312ISMHSYSQKIV1Bos taurus
Y363GSESLYLAPGG3Bos taurus, Mus musculus, Rattus norvegicus
Y363GSETLYLAPGG1Homo sapiens

Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas